Short-term efficacy and safety outcomes of Brolucizumab in the real-life clinical practice

Author: Chiara Maria Eandi (Italy)

Co-authors: Andrea Montesel, Chiara Maria Eandi

Purpose

To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting

Setting/Venue

Medical Retina Department, Jules Gonin Eye Hospital, Lausanne, Switzerland

Methods

A retrospective case series of patients that received IVT-B with a minimum of two injections performed and at least four weeks of follow-up

Results

Nineteen eyes of 19 patients were included. The total number of IVT-B performed was 58 (mean 3.0 ± 1.0; range 2 - 6) injections per patient and an average follow-up time of 14.4 ± 9.0 (range 4.0 - 35.8) weeks. Mean baseline best-corrected visual acuity was 0.4 ± 0.4 logMAR and at the last follow-up was 0.4 ± 0.6 logMAR (p=0.774). All eyes showed a reduction in retinal thickness, with the central subfield thickness being 477 ± 153 µm at baseline and 373 ± 149 µm at the last follow-up (p=0.041). Intra-retinal fluid was present at baseline in 12 eyes (63%) and in three eyes (16%) at the last follow-up (p=0.065). Sub-retinal fluid was present at baseline in 17 eyes (89%) and at the last follow-up in three eyes (16%, p=0.011). Pigment epithelium detachment was apparent in the 16 eyes (84%) at baseline and was still present in 14 eyes (73%, p=0.811). One adverse event of intraocular inflammation was noted.

Conlusions

In our short-term experience, brolucizumab was highly effective in restoring the anatomy and in stabilizing the visual acuity of eyes with nAMD. Its safety profile should be evaluated carefully and needs further investigations.

Financial Disclosure

None to disclose